Safety and performance of a novel subxiphoidal pacemaker system
Journal of Interventional Cardiac Electrophysiology · 2024
DOI: 10.1007/s10840-024-01778-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Interventional Cardiac Electrophysiology, 2024. Verfasst von Imad Libbus und 6 weiteren Autor:innen. Beteiligte Einrichtung: Calyan Technologies, Saint Paul, MN, USA. imad@calyantech.com. Hauptthemen laut MEDLINE: Pacemaker, Artificial. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Traditional cardiac pacemakers commonly have a range of complications related to the presence of intracardiac leads. A new class of extravascular and leadless pacemakers has recently emerged with the potential to mitigate these complications and expand access to cardiac pacing. The objective of this study is to evaluate the implantation, short-term chronic safety, and performance of a novel subxiphoidal extracardiac pacemaker. METHODS: Normal Yorkshire Cross swine (n = 16) were implanted with the subxiphoidal pacemaker. The pacemaker was inserted through a midline chest incision and clipped to the underside of the sternum, with the stimulation electrode placed on the anterior pericardium. Animals were chronically paced and followed for 90 days post-implant, with periodic measurement of pacing capture threshold (PCT) and electrode impedance. RESULTS: All 16 animals were successfully implanted with the study device. At implant, a consistent average PCT of 2.2 ± 0.4 V at a pulse width of 1.0 ms was observed in all animals, with an average implant impedance of 648 ± 44 Ω. Chronic pacing was programmed at a rate of 60 bpm, an amplitude of 3.4 ± 0.7 V, and a pulse width of 1.0 ms. PCT rose to 4.6 ± 0.8 V at 14 days and stabilized; at 90 days, PCT was 3.8 ± 1.2 V and electrode impedance was 533 ± 105 Ω. All implanted animals completed the study with no clinically significant findings, no clinically significant abnormalities, and with no adverse events that affected animal welfare. CONCLUSIONS: This study demonstrated the safety and feasibility of a novel subxiphoidal extracardiac pacemaker to deliver short-term chronic extravascular therapy. Further studies are required to assess the safety, feasibility, and long-term chronic pacing performance in human subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Calyan Technologies, Saint Paul, MN, USA. imad@calyantech.com.
- University of Minnesota, Minneapolis, MN, USA.
- Calyan Technologies, Saint Paul, MN, USA.
Zitieren
APA
Libbus, I., Tholakanahalli, V., Roukoz, H., Knoper, R., Verma, V., Isac, D., & Manicka, Y. (2024). Safety and performance of a novel subxiphoidal pacemaker system. Journal of Interventional Cardiac Electrophysiology. https://doi.org/10.1007/s10840-024-01778-y
Vancouver
Libbus I, Tholakanahalli V, Roukoz H, Knoper R, Verma V, Isac D, et al. Safety and performance of a novel subxiphoidal pacemaker system. Journal of Interventional Cardiac Electrophysiology. 2024. doi:10.1007/s10840-024-01778-y
BibTeX
@article{Libbus2024,
author = {Libbus, Imad and Tholakanahalli, Venkatakrishna and Roukoz, Henri and Knoper, Ryan and Verma, Varun and Isac, Divya and Manicka, Yatheendhar},
title = {Safety and performance of a novel subxiphoidal pacemaker system},
journal = {Journal of Interventional Cardiac Electrophysiology},
year = {2024},
doi = {10.1007/s10840-024-01778-y}
}
EUVIMED